VERAPAMIL SR TABLET (EXTENDED-RELEASE)
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
16-07-2013
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
VERAPAMIL HYDROCHLORIDE
Available from:
SORRES PHARMA INC
ATC code:
C08DA01
INN (International Name):
VERAPAMIL
Dosage:
240MG
Pharmaceutical form:
TABLET (EXTENDED-RELEASE)
Composition:
VERAPAMIL HYDROCHLORIDE 240MG
Administration route:
ORAL
Units in package:
100/500
Prescription type:
Prescription
Therapeutic area:
MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS
Product summary:
Active ingredient group (AIG) number: 0113846003; AHFS:
Authorization status:
CANCELLED POST MARKET
Authorization date:
2014-06-20
Summary of Product characteristics
PRODUCT MONOGRAPH
PR
VERAPAMIL SR
Verapamil hydrochloride Sustained-Release Tablets, USP
240 mg
Antihypertensive Agent
SORRES PHARMA INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
Date of Revision:
July 16, 2013
Submission Control No: 166101
_ _
_VERAPAMIL SR Product Monograph _
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................18
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................24
PART II: SCIENTIFIC INFORMATION
................................................................................25
PHARMACEUTICAL INFORMATION
..........................................................................25
CLINICAL TRIALS
..........................................................................................................26
DETAILED PHARMACOLOGY
...........................................
Read the complete document
